Please login to the form below

Not currently logged in

CRISPR Therapeutics appoints Dr Tony Coles

He takes up a seat on the Swiss biopharma's board of directors

CRISPR Tony ColesSwiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

He is currently founding investor, chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused neurodegenerative diseases.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track record of success.

“The appointment of Dr Coles is in line with our effort to bring the best talent to CRISPR Therapeutics and rapidly become a leading biopharmaceutical company devoted to discovering and developing novel medicines for patients suffering from diseases with limited treatment options.”

Prior to founding Yumanity Dr Coles served as chairman and chief executive officer of Onyx Pharmaceuticals, which was acquired by Amgen in 2013 for $10.5bn.

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck & Co.

6th January 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?